What Прогинорм Ово Treats: Main Uses and Benefits

This medication is applied across therapeutic domains where additional symptomatic support is needed due to a progesterone deficiency. The therapy is relevant for easing symptoms and conditions associated with insufficient progesterone, which includes threatened miscarriage, protocols for women with a history of recurrent pregnancy loss, and symptoms of Luteal Phase Deficiency.

In clinical settings involving acute or unstable symptom patterns, the preparation may be part of symptomatic management to address pronounced symptoms. For instance, it contributes to the relief of distressing physical symptoms of severe Premenstrual Syndrome (PMS), cyclical breast tenderness, and hormonally-driven painful or irregular menstruation. The therapeutic benefit helps ease the overall symptom burden and supports patients during episodes of heightened discomfort.

“The therapy is relevant in situations that require supplemental support, assists with supporting hormonal stability in conditions where hormonal imbalance causes noticeable physiological strain.”

Quick Fact: Used for managing Cyclical Discomfort

Regulatory References

1. NIH StatPearls on Progestins

Who can and cannot use Прогинорм Ово?

This eligibility profile for Прогинорм Ово (Micronized Progesterone) is strictly governed by regulatory constraints that define permitted and prohibited use populations, as stated in official government prescribing documents.

Who Must Not Use This Medicine (Contraindications)

The medicine is contraindicated and must not be used by individuals with a known history of arterial or venous thromboembolism (blood clots) or severe thrombophlebitis. Absolute prohibitions also apply to patients with a known or suspected breast malignancy, severe hepatic impairment or disease, or undiagnosed abnormal genital bleeding. Use is also barred in cases of known hypersensitivity to any component of the formulation.

Age and Condition Restrictions

Regulatory documents state that safety and efficacy are not established for pediatric use. For women 65 years and over, the product is not intended for certain uses, and specific cautions apply, particularly regarding the risk of probable dementia when combined with estrogens. Conditional use is necessary for patients with renal insufficiency or mild to moderate hepatic dysfunction, where careful monitoring is required.

Pregnancy Status

Use during pregnancy is permitted solely for specific, limited protocols, such as luteal phase support in Assisted Reproductive Technology (ART). Outside of these specific contexts, use is generally restricted, and it is contraindicated if the purpose is to test for pregnancy.

Interactions with Other Medicines and Products

Прогинорм Ово (micronized progesterone) interactions primarily involve changes in the drug's plasma concentration due to metabolic factors and the effect on coadministered hormones.

Medicines that May Alter Progesterone Exposure

Progesterone is extensively metabolized by the liver, primarily through the cytochrome P450 3A4 (CYP3A4) enzyme system. This metabolism is the basis for key pharmacokinetic interactions:

Interaction Type	Examples of Interacting Medicines	Effect on Progesterone Exposure
CYP3A4 Inducers	Rifampin, Phenytoin, Phenobarbital, St. John's Wort	Significantly decreased (risk of reduced efficacy)
CYP3A4 Inhibitors	Ketoconazole	Potential for increased concentration (risk of increased effects)

Other Documented Interactions

• Food: Taking the oral capsule with food, specifically a high-fat meal, has been officially documented to significantly increase the bioavailability and absorption of progesterone.
• Hormone Products: Progesterone has been documented to alter the pharmacokinetics of coadministered hormone replacement products, resulting in increased plasma concentrations of total estrone and equilin when used alongside conjugated estrogens.

Consult regulatory labeling for a complete list of all interacting substances and product classes.

How Прогинорм Ово Works

The core mechanism of Прогинорм Ово (progesterone) involves targeted interaction with Progesterone Receptors (PRs), acting on both genomic (slow) and non-genomic (fast) pathways to modulate key physiological systems.

---

Genomic Modulation of Endometrial Development

This domain centers on binding to nuclear PRs and regulating gene transcription. This alters the cellular makeup and protein synthesis in the uterine lining, leading to the secretory transformation of the endometrium resulting in a state of the endometrium conducive to blastocyst apposition and adherence.

---

Dampening of Uterine Smooth Muscle Activity

The drug's action includes influencing signaling dynamics in the myometrium (uterine muscle). This process reduces cellular excitability and sensitivity to contractile stimuli, thereby promoting uterine quiescence, which results in decreased myometrial tone.

---

Neurosteroid Effects and CNS Modulation

As a neurosteroid, the active substance modulates activity within central nervous system pathways. It interacts with the GABAA receptor complex to enhance inhibitory neurotransmission, modifying neural excitability and leading to an enhanced net inhibitory effect on CNS signaling.

Official Administration Guidelines

Прогинорм Ово (Progynorm Ovo) is an oral medication that is taken according to a specific schedule defined in the official product guidelines.

Dosing and Administration Route

Guideline	Detail
Route of Administration	Oral
Official Adult Dose	1 tablet
Timing	To be taken before a meal
Preparation	The tablet must be swallowed whole and not chewed

Administration Protocol

The administration protocol is based on a defined cyclical schedule for adult patients:

• Daily Dose: Take one (1) tablet once daily.
• Treatment Course: The initial treatment course is 20 consecutive days of daily administration.
• Rest Period: Following the 20-day course, there is a 10-day break during which the medication is not taken.
• Cycle Repetition: The 20-day administration followed by the 10-day break is repeated for a total of three to five courses.

Instructions for Missed Doses

If a dose is missed, the administration continues at the next scheduled time. The dose must not be doubled to compensate for the tablet that was missed, ensuring the correct ongoing dosage is maintained. The entire administration plan is structured around these precise, cyclical instructions, and its effectiveness depends on adherence to the defined dosing and rest periods.

Research evidence / Overview of studies for Прогинорм Ово

---

Evidence for use in Reproductive Support (Recurrent Pregnancy Loss and Threatened Miscarriage)

Research was studied for women facing conditions characterized by fluctuating or episodic manifestations, specifically early pregnancy bleeding (known as threatened miscarriage) and a history of recurrent pregnancy loss. Large-scale Randomized Controlled Trials (RCTs) and subsequent systematic reviews research examined the outcomes related to systemic or functional imbalance, primarily tracking the live birth rate and the incidence of miscarriage.

Studies explored how the treatment was observed in some studies in these populations, particularly in women with threatened miscarriage who also had a history of recurrent miscarriages. Findings describe patterns observed in the studies that involved measured live birth rates for the specific subgroup of women with bleeding who also had a history of prior miscarriages.

What remains uncertain is the consistency of findings when comparing the use of oral versus vaginal administration in these sensitive circumstances. Additionally, research contributes to the broader evidence landscape, but the results apply only to the populations studied.

Evidence for use in Luteal Phase Support during Fertility Procedures

The treatment was evaluated in women undergoing Assisted Reproductive Technology (ART) procedures, such as in vitro fertilization (IVF) and frozen embryo transfer (FET). These studies involved RCTs and non-inferiority trials, which studies monitored outcomes such as clinical pregnancy rate and ongoing pregnancy rate.

Research notes a practice where supplementation was included in many ovarian stimulation protocols due to observed physiological changes during those cycles. Non-inferiority trials research examined outcomes related to systemic or functional imbalance when comparing different administration routes (for example, oral versus vaginal) in specific ART settings.

It is not yet clear whether the oral administration route provides the same patterns observed as the vaginal route for all types of ART protocols. Long-term effects are not fully established regarding the optimal dose and evidence quality varies across studies when evaluating the different available administration routes in all specific ART cycles.

Evidence for Cyclical Symptoms (Premenstrual Syndrome and Discomfort)

Research was studied for conditions where symptoms may vary in intensity, focusing on women diagnosed with severe Premenstrual Syndrome (PMS) and outcomes related to physical discomfort, such as cyclical breast tenderness. Studies report how symptoms evolved in the observed populations over defined time intervals. The systematic reviews examining this body of research findings were mixed regarding changes in overall symptom scores.

Comparative evidence is lacking to fully contextualize how the treatment was evaluated in this patient population relative to other forms of support. The overall evidence certainty remains low based on systematic reviews due to evidence quality varies across studies and limitations in trial design.

Key Studies & References Progestins (NIH StatPearls)

Common questions about Прогинорм Ово (FAQ)

---

Q: Can Прогинорм Ово make me feel sleepy or dizzy?

Official regulatory documents list dizziness and somnolence (sleepiness) as common side effects associated with this medication. Regulatory notes indicate that these effects may be transient (temporary) and are often reported to occur within a few hours following oral administration.

---

Q: What is the full administration schedule, including the breaks?

According to the official product information, the administration is based on a defined cyclical schedule. The pattern is structured as a course of 20 consecutive days of use, followed by a 10-day period where the medicine is not used. This cycle is then intended to be repeated for a specified number of courses, typically three to five.

---

Q: What is the main action of Прогинорм Ово?

The general purpose is to provide hormonal supplementation to support the reproductive system and address conditions related to luteal insufficiency (a deficiency of the natural hormone). The active ingredient works by activating progesterone receptors, which helps to prepare and mature the uterine lining.

---

Q: How long does it take for this medication to start working?

Pharmacokinetic studies show that after oral administration, the concentration of the hormone in the blood usually reaches its highest level within about three hours. It is important to note that the time it takes to observe clinical effects and individual response can vary significantly.

---

Q: Can men take this medicine?

Regulatory documents state that this medicine is indicated for use only in women for specific conditions, such as luteal support or certain types of hormone replacement therapy. Official labeling does not contain any approved indications for its use in male patients.

---

Q: Does it interact with birth control pills?

Regulatory information focuses on how the drug interacts with medicines that affect liver enzymes (CYP3A4 inducers) and other hormones. Because some interacting medicines affect the processes that break down hormones, there is a potential for changes in the concentration of progestins. Official product information is often generalized and may not explicitly list every hormonal contraceptive.

---

Q: What is the difference between oral and vaginal administration of progesterone?

The oral route is processed through the digestive system and the liver, which can affect the drug's overall availability in the body. Research is ongoing to compare the outcomes and bioavailability of the oral route versus the vaginal route for specific medical indications.

Storage Requirements

This medicine must be stored according to regulatory requirements to preserve its stability and effectiveness. The product should be kept at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F). Storage conditions must protect the capsules from freezing, excess heat, direct light, and moisture.

The capsules must remain in their original container and the container must be kept tightly closed when not in use. To ensure child safety, the product, and all medicine, must be stored in a secure location, out of the sight and reach of children.

Disposal Instructions

Do not use outdated or expired medicine. Disposal of unused capsules, waste material, and any single-use applicators must be conducted in accordance with local requirements. This regulatory instruction prevents the discarding of medicinal waste via household trash or wastewater. Patients are directed to consult a healthcare professional regarding local collection points for proper pharmaceutical waste disposal.